Hi. Good afternoon everyone. As was said, my name is Tim Moran. I run the Avertix Medical Group, and I'm really happy to be back here at LSI and have the chance to tell you the story and tell you some of the steps that we've taken over the last 12 months. So let me just start and give you kind of the headline here. What a verdicts has created is the first implantable predictive diagnostic, and the whole design of this device is focused for getting patients who are having a heart attack to care much more quickly, because we know that that delay time equals muscle, right? So we've developed the device. It's a PMA device. It's approved it on the market, and basically it will both monitor and then alert the patient in real time when it senses the onset of a heart attack. So let's talk just a little bit about the business. We're a lean team, but we've tried to assemble folks with the expertise that we needed. We brought in a new sales leader this past year that came to us from shockwave medical and had a history at Abiomed, one of our original founders, who now serves as the chief technology officer, excellent engineer that came from Bell Labs. We brought in a very strategic CFO, and we have a gentleman that heads up our R and D efforts that has been involved with many of the large cardiac strategics and development of products over the years. So let's talk a little bit about the problem. You're probably all familiar that you know, there's a significant prevalence of heart attack. If you look at just the United States, it's been pretty consistent over the last many years. There's about 800,000 heart attacks that occur each year in the US, about 60 or 65% of those are first time events, and about 30% of those are someone having a recurrent heart attack. Unfortunately, once you've had a heart attack, you automatically are in a high risk category, so the potential to have another event goes up significantly. The literature would tell you that about 25% of these patients will end up having another event in the next two to five years. Unfortunately, about 20% of all heart attacks are completely silent, so there's no symptoms at all until there's significant damage to the patient's heart muscle, up to 45 or 50% of these per these incidents are silent or atypical. So if you think about women, it's a it's a big category that they do not present the same way when they're having a cardiac event, which often leads to kind of ignoring the symptoms, and ended up arriving for care much too late. And then finally, what we know is every hour, as I said, time is muscle. Every hour matters. So you see the mortality increase that goes up in just three to four hours of delay from the onset of your coronary artery getting occluded to actually getting it open back up. And if you think about what's happening on the market today in terms of treatments, this is the way we like to kind of categorize the space. So if someone has a acute myocardial infarction, a heart attack, one of the key indicators that are going to get measured after they have that attack is what's their ejection fraction. So how well is their heart pumping blood each time that it beats? If you look at this scale up here, if a patient has a significant heart attack and their EF gets so compromised that it's at 35% or less, they're therefore eligible to have an implantable cardiac defibrillator or ICD, which is a very large and established market, which folks are probably very familiar with. What's incredible about that is only 10% of the annual heart attacks. Someone ends up with EF less than 35 so what we're focused on is this middle area. About 80% of the patients have a heart attack. Their EF is somewhere between, call it 35 and 55 so they're still highly compromised. Typically, they have other comorbidities, such as obesity, hypertension, smoker, all of these things that raises and elevates their risk. And when you look at the market today, really the only treatment that they have are either medication, right? So they might be on beta blockers or other drugs, and the physician, obviously will try to influence them to, you know, change their lifestyle and ensure that they come for follow up appointments. Unfortunately, we all know that that doesn't always happen, as we would like, right? So these patients remain un monitored, out out in, you know, living their life, and the doc may not see them again until they have their second attack, which oftentimes can be too late. So this is exactly where we focused when we created the Guardian device. So let me share a little bit more about this device. What's really interesting is it's very similar to that in form factor of a pacemaker. So we're making an incision in the upper upper left chest pocket. We're implanting our device that you see there, it looks just like a pacemaker. The physician either an intervention. Cardiologist or an electrophysiologist, is running a single lead from our device into the apex of the right ventricle. This is a procedure that is very well defined. It's identical to that of a pacer. So it's been done for 40 or 50 years, typically done on an outpatient basis, 30 to 35 minutes, where the secret sauce really comes with our device is how we actually monitor this patient from that point forward, and how we alert them at the onset of an event. So you see the two other components here. We have a patient handheld and we have a programmer. Basically when this device gets implanted in the patient from that day forward, every 90 seconds, the device wakes up, it looks at the patient's specific electrogram. So we're establishing a patient specific baseline of their normal EKG rhythm from inside their heart, and we're looking for very minute shifts in their ST segment, which would be kind of the gold standard way to determine if it's the onset of a heart attack occurring. You know, typically, the only way you're going to get this is if a patient was at an E was at an ER and was hooked up to a 12 lead EKG so think about it as putting an EKG machine inside of these high risk patients that then looks for occurrence of risk every 90 seconds. If we detect a heart attack, the patient is going to get notified immediately. In real time, the device will vibrate in the patient's chest. We also have the small hand held that will provide both audio and visual alerting as a backup. The program is very typical devices like this. So that's used for parameter setting if the physician wants to, you know, change settings to look at specific things for that that that patient. So we have two different notifications that occur. So for the primary purpose of the device, which is heart attack detection, they're going to get the emergency alarm that's going to occur as outlined, as I just talked about. But because we have the lead in the heart, and we're in this patient's heart for six years, we're picking up a whole host of other cardiac arrhythmias that can occur. So during our large pivotal trial, we picked up, as you'd imagine, atrial fibrillation, ventricular tachycardia, bundle, Branch, block, a lot of different things. So when we got our approval with the FDA, what we all realized was that's important information as well. So we have a different alert, which is called a C Doctor alert, and the patients are trained that if you get a C Doctor alert, which has a different vibratory pattern, a different audio visual alert, they're to call their physician office and schedule an appointment within 72 hours. It gives the doc then the ability to look at the data, interrogate it, and decide, do I really need to bring them in? Or was this like a short bout of AFib that, you know, we can watch and wait? So it gives them a lot more kind of around the clock monitoring of this patient population during our trial that we did the pivotal trial to get our approval, we had about 907 patients. We had a treatment and a control arm. The two things that really led to and drove our approval were, one, the reduction in time to door. So as I said at the outset, you know, people ignore symptoms. They think it's gi related or muscle a muscle pull, and they wait and wait and wait until it's too late. So in our trial, we measured any patients that had an MI, patients that did not have the benefit of the Guardian, took, on average, 12.7 hours to get themselves to an ER when they had the benefit of the guardian. We had an 8x reduction. So we got every patient there in less than two hours, and the average was 1.6 hours, which obviously was very significant. What that led to is you'll see on the right side of this screen, the outcome was, we preserved ejection fraction. So you see patients that had an ejection fraction in the mid 50s prior to an event, if they had the benefit of all that time saved when they were discharged after the event, they stayed in that same range, so 54.1 down to 53.3 so that's really significant. We're keeping people out of kind of sliding down that EF scale, where they ultimately need an ICD, or they're headed towards heart failure, which obviously is not a good outcome. The other thing that we detected during the trial was 42 silent heart attacks. So really incredible. Patient has no symptoms at all. Their vibration goes off in their chest. They're getting the alert. They're like, Okay, well, I was trained to go to the doctor and or go to the ER, so they go to the ER, and sure enough, they had a significant enough occlusion that needed to be restored and scented. So when we look at this market, as I said, you know, if you think about focusing on that middle 80% of patients post MI, it's a massive white space for us. You know, total addressable patients, based on our indication, would tell you there's about 640,000 each year in the US. Clearly, since we're in early commercialization, we've narrowed that down a bit. We're focused on patients that, you know, have just had their first MI, but also have significant comorbidities that would put them at even higher risk. And those are the ones that the physicians are saying, Yeah, it's really obvious this person will benefit from having the Guardian device, but you're looking at, you know, multi billion dollar operating. Opportunity from a space perspective. The great news we received earlier this year, on January 1, we were able to get reimbursement for our device. So we're now reimbursed under a PC five, two to four, which pays around $20,000we charge about $13,000 for the device. So that works very well for us, and it's real tail wind. I'll just one, one quick comment on commercialization. So we're trying to deploy capital in a very efficient manner. So we have very focused markets, three or four markets where we've gone in partner with some, you know, the leading institutions and KOLs, to show that we've figured out the commercial effort, basically de risk commercialization, and show that we have repeat implants happening each quarter. So that's a continued effort. And you know, the theme I would take away here is we've tried to do everything to de risk the business, and the last phase, now that we're finalizing, is commercialization. So thanks very much for listening, and if you'd like to have further conversations, I'll be right outside. Thank you.